Logo image
Sign in
Back
Torque teno virus viremia and QuantiFERON®-CMV assay in prediction of cytomegalovirus reactivation in R+ kidney transplant recipients
Journal article   Open access   Peer reviewed

Torque teno virus viremia and QuantiFERON®-CMV assay in prediction of cytomegalovirus reactivation in R+ kidney transplant recipients

Sarah Mafi, Marie Essig, Jean-Philippe Rerolle, Gisèle Lagathu, Romain Crochette, Véronique Brodard, Betoul Schvartz, Stephanie Gouarin, Nicolas Bouvier, Ilka Engelmann, …
Frontiers in Medicine, Vol.10
22/06/2023
DOI: https://doi.org/10.3389/fmed.2023.1180769

Abstract

Clinical trial registration: ClinicalTrials.gov registry identifier NCT02064699 Torquetenovirus cytomegalovirus QuantiFERON ® CMV kidney transplantation CMV-seropositive recipients Clinical trial registration: ClinicalTrials.gov registry identifier NCT02064699 Torquetenovirus cytomegalovirus QuantiFERON ® CMV kidney transplantation CMV-seropositive recipients
Conclusion: The combination of TTV load and QF-Ag or TTV load and QF-Mg could be useful in stratifying the risk of CMV reactivation in R+ KTR during the first post-transplant year and thereby have an impact on the duration of prophylaxis in these patients.
url
Find in HALView
url
https://doi.org/10.3389/fmed.2023.1180769View
Published (Version of record) Open

Metrics

1 Record Views

Details

Logo image